September 19, 2021

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for etesevimab (JS016/LY-CoV016)

Read More

Taliban reopen schools for Afghan boys

The Taliban allowed boys in classes six to 12 to attend school and male teachers to resume teaching across Afghanistan from Saturday. “All male teachers and students should attend their educational institutions,” a Taliban statement said ahead of clas…

Read More

Recent Posts